Ann Van de Velde

1.2k total citations
29 papers, 373 citations indexed

About

Ann Van de Velde is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ann Van de Velde has authored 29 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Ann Van de Velde's work include Immunotherapy and Immune Responses (9 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). Ann Van de Velde is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). Ann Van de Velde collaborates with scholars based in Belgium, Netherlands and United Kingdom. Ann Van de Velde's co-authors include Zwi Berneman, Wilfried Schroyens, Jan Michiels, Marc van der Planken, Viggo Van Tendeloo, Alain Gadisseur, Nathalie Cools, Sébastien Anguille, Evelien Smits and Huub H.D.M. van Vliet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ann Van de Velde

26 papers receiving 363 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ann Van de Velde 153 124 121 79 62 29 373
Marina E. Fomin 107 0.7× 176 1.4× 103 0.9× 29 0.4× 56 0.9× 18 495
N Carpentier 99 0.6× 88 0.7× 253 2.1× 48 0.6× 26 0.4× 17 482
Chantal Eijsink 92 0.6× 64 0.5× 314 2.6× 44 0.6× 155 2.5× 16 596
Ushani Srenathan 76 0.5× 71 0.6× 263 2.2× 48 0.6× 15 0.2× 6 381
Wolfgang Helmberg 225 1.5× 81 0.7× 214 1.8× 23 0.3× 34 0.5× 35 497
Oliver Schönborn‐Kellenberger 29 0.2× 230 1.9× 65 0.5× 155 2.0× 26 0.4× 27 403
Kees Sintnicolaas 145 0.9× 82 0.7× 222 1.8× 31 0.4× 20 0.3× 21 512
Ondřej Pelák 37 0.2× 78 0.6× 186 1.5× 27 0.3× 22 0.4× 13 343
Alice Kok 78 0.5× 92 0.7× 225 1.9× 62 0.8× 94 1.5× 11 488
Robert A. Dunstan 268 1.8× 40 0.3× 101 0.8× 32 0.4× 18 0.3× 22 474

Countries citing papers authored by Ann Van de Velde

Since Specialization
Citations

This map shows the geographic impact of Ann Van de Velde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Van de Velde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Van de Velde more than expected).

Fields of papers citing papers by Ann Van de Velde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Van de Velde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Van de Velde. The network helps show where Ann Van de Velde may publish in the future.

Co-authorship network of co-authors of Ann Van de Velde

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Van de Velde. A scholar is included among the top collaborators of Ann Van de Velde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Van de Velde. Ann Van de Velde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meers, Stef, Koen Theunissen, Koen Van Eygen, et al.. (2024). Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives. SHILAP Revista de lepidopterología. 5(5). 1096–1099.
2.
3.
Meers, Stef, Ann De Becker, Kristien Wouters, et al.. (2023). Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study. Cancers. 15(13). 3296–3296. 2 indexed citations
4.
Delforge, Michel, Sébastien Anguille, Julien Depaus, et al.. (2023). P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison. Clinical Lymphoma Myeloma & Leukemia. 23. S170–S170. 1 indexed citations
5.
6.
Verlinden, Anke, Véronique De Vroey, Herman Goossens, et al.. (2019). COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY.. Mediterranean Journal of Hematology and Infectious Diseases. 11(1). e2019023–e2019023. 9 indexed citations
7.
Janssens, Ann, Yves Béguin, Catherine Lambert, et al.. (2019). PF694 TREATMENT‐FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM. HemaSphere. 3(S1). 301–301. 1 indexed citations
8.
Laureys, Guy, Barbara Willekens, Ludo Vanopdenbosch, et al.. (2018). A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurologica Belgica. 118(2). 161–168. 7 indexed citations
9.
Craenenbroeck, Amaryllis H. Van, Evelien Smits, Sébastien Anguille, et al.. (2014). Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells. Transplantation. 99(1). 120–127. 25 indexed citations
10.
Selleslag, Dominik, Catherine Lambert, Pierre Zachée, et al.. (2014). Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium. Acta Clinica Belgica. 70(1). 16–22. 1 indexed citations
11.
12.
Berneman, Zwi, Ann Van de Velde, Sébastien Anguille, et al.. (2012). WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.. Journal of Clinical Oncology. 30(15_suppl). 2506–2506. 4 indexed citations
13.
Gulck, Ellen Van, Erika Vlieghe, Marc Vekemans, et al.. (2011). mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 26(4). F1–F12. 89 indexed citations
14.
Cools, Nathalie, B. Stein, Ann Van de Velde, et al.. (2010). Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. Journal of Immunological Methods. 354(1-2). 1–10. 23 indexed citations
15.
Delforge, Michel, Hilde Demuynck, Philippe Mineur, et al.. (2009). International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.. Blood. 114(22). 4523–4523. 1 indexed citations
16.
Berneman, Zwi, Ann Van Driessche, Ann Van de Velde, et al.. (2007). Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial.. Blood. 110(11). 158–158. 2 indexed citations
17.
Michiels, Jan, Zwi Berneman, Alain Gadisseur, et al.. (2006). Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease. Clinical and Applied Thrombosis/Hemostasis. 12(4). 397–420. 39 indexed citations
18.
Michiels, Jan, Alain Gadisseur, Ulrich Budde, et al.. (2005). Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences. Seminars in Thrombosis and Hemostasis. 31(5). 577–601. 26 indexed citations
19.
Regenmortel, Niels Van, Hendrik De Raeve, Serge A.R.B. Rombouts, et al.. (2005). Bortezomib-induced Sweet's syndrome.. PubMed. 90(12 Suppl). ECR43–ECR43. 28 indexed citations
20.
Michiels, Jan, Ann Van de Velde, Huub H.D.M. van Vliet, et al.. (2002). Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications. Seminars in Thrombosis and Hemostasis. 28(2). 111–132. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina E. Fomin Breakdown of academic impact, for papers by N Carpentier Breakdown of academic impact, for papers by Chantal Eijsink Breakdown of academic impact, for papers by Ushani Srenathan Breakdown of academic impact, for papers by Wolfgang Helmberg Breakdown of academic impact, for papers by Oliver Schönborn‐Kellenberger Breakdown of academic impact, for papers by Kees Sintnicolaas Breakdown of academic impact, for papers by Ondřej Pelák Breakdown of academic impact, for papers by Alice Kok Breakdown of academic impact, for papers by Robert A. Dunstan
Rankless by CCL
2026